• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vir Biotechnology Inc (NQ: VIR )

    8.760 -0.090 (-1.02%)
    Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 295,130
    Open 8.920
    Bid (Size) 8.700 (8)
    Ask (Size) 8.900 (10)
    Prev. Close 8.850
    Today's Range 8.740 - 9.030
    52wk Range 7.610 - 24.99
    Shares Outstanding 133,976,538
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
    From Vir Biotechnology, Inc.
    Via Business Wire
    Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
    Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT normalization rates with tobevibart and elebsiran. 
    Via Benzinga

    Performance

    YTD
    -16.65%
    -16.65%
    1 Month
    -17.59%
    -17.59%
    3 Month
    -9.60%
    -9.60%
    6 Month
    -13.10%
    -13.10%
    1 Year
    -64.08%
    -64.08%

    More News

    Read More
    Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Evaluating Vir Biotechnology: Insights From 5 Financial Analysts
    Via Benzinga
    Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
    Via Benzinga
    Assessing Vir Biotechnology: Insights From 5 Financial Analysts
    Via Benzinga
    Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
    From Vir Biotechnology, Inc.
    Via Business Wire
    Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024
    Via InvestorPlace
    Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
    From Vir Biotechnology, Inc.
    Via Business Wire
    Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
    From Vir Biotechnology, Inc.
    Via Business Wire
    From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
    Via InvestorPlace
    Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
    Via InvestorPlace
    Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
    From Vir Biotechnology, Inc.
    Via Business Wire
    3 Highly Rated Biotech Stocks to Buy for 300% Gains
    Via InvestorPlace
    Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
    From Vir Biotechnology, Inc.
    Via Business Wire
    Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.